Nicholas Simmonds

Sep 26, 2024 | erj.ersjournals.com | Peter Middleton |Nicholas Simmonds

Footnotes Conflict of interest: P.G. Middleton reports grants from HCF Australia and the Canadian Institutes of Health, consultancy fees from Vertex Pharma, payment or honoraria for lectures, presentations, manuscript writing or educational events from Vertex Pharma, AstraZeneca and Limbic, payment for expert testimony from Shine Lawyers, support for attending meetings from NSW Health, participation on a data safety monitoring board or advisory board with Cystic Fibrosis Foundation, is a...

Jun 12, 2023 | onlinelibrary.wiley.com | Peter Middleton |Nicholas Simmonds |Falk Libby E

Abstract Bronchiectasis is often considered progressive and irreversible, so cases of regression or reversal are an important step in understanding the underlying pathophysiological mechanisms. Cystic fibrosis, (CF) caused by pathogenic variants in the cystic fibrosis transmembrane conductance regulator (CFTR) gene has been a success story in personalized medicine. The recent development of CFTR modulator therapies has revolutionized care.